EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GNA11 Variants Identified in Patients with Hypercalcemia or Hypocalcemia

Sarah A Howles iD, Caroline M Gorvin iD, Treena Cranston, Angela Rogers, Anna K Gluck, Hannah Boon, Kate Gibson, Mushtaqur Rahman, Allen Root, M Andrew Nesbit, Fadil M Hannan, Rajesh V Thakker iD

Journal of Bone and Mineral Research · 2020

DOI: 10.1002/jbmr.4803 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Bone and Mineral Research, 2020. Verfasst von Sarah A Howles und 11 weiteren Autor:innen. Beteiligte Einrichtung: Academic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Hypercalcemia, Hypocalcemia. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, Department of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Familial hypocalciuric hypercalcemia type 2 (FHH2) and autosomal dominant hypocalcemia type 2 (ADH2) are due to loss- and gain-of-function mutations, respectively, of the GNA11 gene that encodes the G protein subunit Gα11, a signaling partner of the calcium-sensing receptor (CaSR). To date, four probands with FHH2-associated Gα11 mutations and eight probands with ADH2-associated Gα11 mutations have been reported. In a 10-year period, we identified 37 different germline GNA11 variants in >1200 probands referred for investigation of genetic causes for hypercalcemia or hypocalcemia, comprising 14 synonymous, 12 noncoding, and 11 nonsynonymous variants. The synonymous and noncoding variants were predicted to be benign or likely benign by in silico analysis, with 5 and 3, respectively, occurring in both hypercalcemic and hypocalcemic individuals. Nine of the nonsynonymous variants (Thr54Met, Arg60His, Arg60Leu, Gly66Ser, Arg149His, Arg181Gln, Phe220Ser, Val340Met, Phe341Leu) identified in 13 probands have been reported to be FHH2- or ADH2-causing. Of the remaining nonsynonymous variants, Ala65Thr was predicted to be benign, and Met87Val, identified in a hypercalcemic individual, was predicted to be of uncertain significance. Three-dimensional homology modeling of the Val87 variant suggested it was likely benign, and expression of Val87 variant and wild-type Met87 Gα11 in CaSR-expressing HEK293 cells revealed no differences in intracellular calcium responses to alterations in extracellular calcium concentrations, consistent with Val87 being a benign polymorphism. Two noncoding region variants, a 40bp-5'UTR deletion and a 15bp-intronic deletion, identified only in hypercalcemic individuals, were associated with decreased luciferase expression in vitro but no alterations in GNA11 mRNA or Gα11 protein levels in cells from the patient and no abnormality in splicing of the GNA11 mRNA, respectively, confirming them to be benign polymorphisms. Thus, this study identified likely disease-causing GNA11 variants in <1% of probands with hypercalcemia or hypocalcemia and highlights the occurrence of GNA11 rare variants that are benign polymorphisms. © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypercalcemiaHypocalcemiaGTP-Binding Protein alpha SubunitsMutationReceptors, Calcium-SensingHumansHEK293 CellsCalciumHypoparathyroidismHypercalciuria

Stichwörter der Autor:innen

CALCIUM-SENSING RECEPTORCELL/TISSUE SIGNALING-ENDOCRINE PATHWAYSFAMILIAL HYPOCALCIURIC HYPERCALCEMIAG PROTEIN-COUPLED RECEPTORS

Substanzen

CalciumReceptors, Calcium-SensingGNA11 protein, humanGTP-Binding Protein alpha Subunits

Autor:innen und Institutionen

  • Academic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
  • Oxford Molecular Genetics Laboratory, Churchill Hospital, Oxford, UK.
  • Department of Endocrinology, Northwick Park Hospital, North West London Hospitals NHS Trust, Harrow, UK.
  • Department of Endocrinology, John Hopkins All Children's Hospital, St. Petersburg, Florida, USA.
  • Biomedical Sciences Research Institute, University of Ulster, Coleraine, UK.

ORCID-Profile: Sarah A Howles, Caroline M Gorvin, Rajesh V Thakker

Förderung

  • Wellcome Trust
  • Medical Research Council
  • Department of Health
  • Horizon 2020 Framework Programme
  • National Institute for Health and Care Research

Zitieren

APA

Howles, S. A., Gorvin, C. M., Cranston, T., Rogers, A., Gluck, A. K., Boon, H., Gibson, K., Rahman, M., Root, A., Nesbit, M. A., Hannan, F. M., & Thakker, R. V. (2020). GNA11 Variants Identified in Patients with Hypercalcemia or Hypocalcemia. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.4803

Vancouver

Howles SA, Gorvin CM, Cranston T, Rogers A, Gluck AK, Boon H, et al. GNA11 Variants Identified in Patients with Hypercalcemia or Hypocalcemia. Journal of Bone and Mineral Research. 2020. doi:10.1002/jbmr.4803

BibTeX
@article{Howles2020,
  author = {Howles, Sarah A and Gorvin, Caroline M and Cranston, Treena and Rogers, Angela and Gluck, Anna K and Boon, Hannah and Gibson, Kate and Rahman, Mushtaqur and Root, Allen and Nesbit, M Andrew and Hannan, Fadil M and Thakker, Rajesh V},
  title = {GNA11 Variants Identified in Patients with Hypercalcemia or Hypocalcemia},
  journal = {Journal of Bone and Mineral Research},
  year = {2020},
  doi = {10.1002/jbmr.4803}
}
Kostenlos starten →